

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 10D2097728	(X3) Date Survey Completed 09/24/2020
Name of Provider or Supplier Genesiscare Usa Of Florida Llc DbA	Street Address, City, State 20601 E Dixie Hwy Ste 330, Aventura, FL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	A desk review survey of the laboratory's proficiency test results was performed on September 24, 2020 for Integrated Oncology of south Florida. The laboratory, Integrated Oncology of South Florida, is not in compliance with Code of Federal Regulations (CFR), Part 493, Laboratory Requirements.
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the laboratory's proficiency testing records for 2019 and 2020, the laboratory had subsequent unsuccessful performance in proficiency testing in the specialty of hematology. Refer to D2130. Findings include: Review of the Medical Laboratory Evaluation (MLE) proficiency testing records and the review of the

	Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports, on September 24, 2020 at 10:00 AM, showed that the laboratory had unsatisfactory testing scores for the analytes, white blood cell count and white blood cell differential for three out of four testing events in 2019 and 2020.
D2130	HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on the review of the Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports and the laboratory's proficiency testing records, the laboratory had subsequent unsuccessful participation in proficiency testing in the specialty of hematology. Findings include: On September 24, 2020 on or about 10:00 AM the Medical Laboratory Evaluation (MLE) proficiency testing records and the CMS 153 and 155 reports were reviewed. The review showed that the laboratory had unsuccessful proficiency testing scores for three out of four testing events for the analytes, white blood cell count (WBC) and white blood cell differential (WBC diff), as shown below. Event #2, 2019 WBC-0% WBC diff-0% Event #1, 2020 WBC-0% WBC diff-0% Event #2, 2020 WBC-60% WBC diff-4%
D6000	MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on the review of the laboratory's proficiency testing records, the laboratory director failed to ensure that the laboratory maintained a satisfactory score for proficiency testing in the specialty of hematology. Findings include: On September 24, 2020, on or about 10:00 AM, the Medical Laboratory Evaluation (MLE) proficiency records and the Centers for Medicare & Medicaid Service (CMS) 153 and 155 reports were reviewed. The review showed that the laboratory had subsequent unsatisfactory proficiency testing scores for the analytes, white blood cell count (WBC) and white blood cell differential (WBC Diff), in the specialty of hematology. The laboratory director is responsible for ensuring that the laboratory maintains successful participation in proficiency testing. Refer to D2130.
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:

Based on the review of the laboratory's proficiency testing scores, the laboratory director failed to ensure that the laboratory performed proficiency testing in such a manner as to achieve and maintain successful participation in proficiency testing in the specialty of hematology. Findings Include: The review of the Medical Laboratory Evaluation (MLE) proficiency testing records and the Centers for Medicare & Medicaid Services (CMS) 153 and 155 reports on September 24, 2020 on or about 10:00 AM showed that the laboratory received unsatisfactory proficiency testing scores for three out of four testing events as shown below. Event #2, 2019 WBC-0% WBC diff-0% Event #1, 2020 WBC-0% WBC diff-0% Event #2, 2020 WBC-60% WBC diff-4%